...
首页> 外文期刊>Transplant immunology >J2 prolongs the corneal allograft survival through inhibition of the CD4(+) T cell-mediated response in vivo.
【24h】

J2 prolongs the corneal allograft survival through inhibition of the CD4(+) T cell-mediated response in vivo.

机译:J2通过抑制体内CD4(+)T细胞介导的反应来延长同种异体角膜的存活。

获取原文
获取原文并翻译 | 示例
           

摘要

In our previous report, we described a novel non-peptidic organic ligand of CD4 D1, designated J2, as a potential inhibitor of CD4 D1 and thus CD4-dependent T cell responses in vitro. In this work, we further used a murine model of corneal allograft rejection to determine its in vivo immunosuppressive activities. To mimic the situation in high-risk human eyes, the recipient mice corneas were all induced by intrastromal sutures to serve as neovascularized graft beds. J2 was administrated by mouth 3 h before transplantation and thereafter on consecutive 12 days. The results showed that J2 could significantly prolong the median survival time of the corneal allografts, compared to the untreated control group. And the subsequent functional assays, including T cell phenotype analysis, delayed-type hypersensitivity (DTH) and enzyme-linked immunospot (ELISPOT) assays revealed that the immunosuppressive activity of J2 was associated with its inhibitory effects on the CD4(+) T cells and these cells-mediated responses. All these results suggest that J2 is a potential lead for the development of new immunosuppressive agents to prevent the corneal allograft rejection.
机译:在我们之前的报告中,我们描述了一种新型的CD4 D1非肽类有机配体,称为J2,是CD4 D1的潜在抑制剂,因此是体外依赖CD4的T细胞应答。在这项工作中,我们进一步使用了小鼠角膜同种异体移植排斥模型来确定其体内免疫抑制活性。为了模拟高风险人眼中的情况,基质内缝线均将受体小鼠角膜全部用作新生血管移植床。移植前3小时及之后连续12天口服J2。结果表明,与未治疗的对照组相比,J2可以显着延长同种异体角膜的中位存活时间。随后的功能测定包括T细胞表型分析,迟发型超敏反应(DTH)和酶联免疫斑点(ELISPOT)测定表明,J2的免疫抑制活性与其对CD4(+)T细胞和CD4(+)细胞的抑制作用有关。这些细胞介导的反应。所有这些结果表明,J2是开发新的免疫抑制剂以防止同种异体角膜排斥反应的潜在先导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号